Objective The purpose of this study is to explore programmed death-ligand 1(PD-L1)expression and its effect on prognosis of anal squamous cell carcinoma(ASCC)patients,so as to provide clinical basis for immunotherapy in ASCC patients.Method This is a retrospective study,and the clinical data of patients(n=20)who were diagnosed as stage Ⅱ-Ⅲ ASCC and received curative chemoradiotherapy in the First Affiliated Hospital of Sun Yat-sen University between May 2016 and January 2024 were collected.PD-L1 expression levels in tumor samples(n=14)were tested by immunohistochemistry technique.PD-L1 expression intensity was evaluated by combined positive score(CPS).PD-L1 positive criterion was CPS≥1,and patients were divided into PD-L1 high-expression group(CPS≥20,n=7)and low-expression group(CPS＜20,n=7)according to the median value of CPS.The comparison of survival between PD-L1 high-expression group and low-expression group was calculated with the Log-rank test.Result The median follow-up time of 20 patients was 33.4 months.The 3-year overall survival(OS)rate,progression-free survival(PFS)rate,local-regional recurrence free survival(LRFS)rate and distance-metastasis free survival(DMFS)rate for all patients were 83.9%,78.6%,92.9%and 85.7%,respectively.Immunohistochemistry results of PD-L1 in 14 patients'tumor samples were all positive(CPS≥1).In survival analysis,the 3-year OS rate of patients with PD-L1 high-expression and PD-L1 low-expression were 80.0%and 100%(P=0.371),3-year PFS rate were 60.0%and 100%(P=0.134),3-year LRFS rate were 100%and 100%(P=1.000),and 3-year DMFS rate were 60.0%and 100%(P=0.134),respectively.Conclusion PD-L1 was highly expressed in ASCC patients,and there was no significant difference in survival prognosis between PD-L1 high-expression and PD-L1 low-expression groups.
维普
万方数据